Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · Real-Time Price · USD
2.830
-0.030 (-1.05%)
At close: Aug 28, 2026, 4:00 PM EDT
2.850
+0.020 (0.71%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Company Description
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.
Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019.
Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Boundless Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Jessica Oien |
Contact Details
Address: 10955 Alexandria Way, Suite 100 San Diego, California 92121 United States | |
| Phone | 858 766 9912 |
| Website | boundlessbio.com |
Stock Details
| Ticker Symbol | BOLD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1782303 |
| CUSIP Number | 10170A100 |
| ISIN Number | US10170A1007 |
| Employer ID | 83-0751369 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jessica Oien J.D. | President, Principal Executive Officer, Chief Legal Officer and Corporate Secretary |
| David Hinkle | Senior Vice President of Finance, Controller and Corporate Treasurer |
| Meredith Wesley | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2026 | 425 | Filing |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 27, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 7, 2026 | 10-Q | Quarterly Report |
| Jun 29, 2026 | SCHEDULE 13G | Filing |
| Jun 23, 2026 | 425 | Filing |
| Jun 23, 2026 | 8-K | Current Report |
| Jun 17, 2026 | 8-K | Current Report |